ArticleCancers2011
Assessment of the evolution of cancer treatment therapies.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 289 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
289 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Bibliometric analysis of knowledge maps and future trends of TIM-3 in cancer.Frontiers in oncology · 2026Pooled it
- Mapping the intellectual structure and emerging trends on nanomaterials in colorectal cancer: a bibliometric analysis from 2003 to 2024.Frontiers in oncology · 2024Pooled it
- Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials.Nutrients · 2021Pooled it
- Integration of Ayurveda in managing chemotherapy-induced hand-foot-skin reaction-an exploratory quasi experimental study.Frontiers in medicine · 2025Trial
- Prevalence and factors associated with chemotherapy induced peripheral neuropathy among adult patients with cancer at Mbarara Regional Cancer Centre: a cross-sectional study.BMC neurology · 2026Article
- Protective effects of propofol, ketamine, and their combination against HScientific reports · 2026Article
- Structural Lipidomics Uncovers CC Location-Specific Lipid Signatures and the Response to Immune Checkpoint Inhibitor in dMMR/MSI‑H Colorectal Cancer.ACS measurement science au · 2026Article
- Global research trends and emerging frontiers of nanozymes in cancer therapy based on bibliometric and knowledge mapping analysis from 2001 to 2025.Discover nano · 2026Review
- Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation.Cancer chemotherapy and pharmacology · 2026Article
- Chemotherapeutic efficacy of nano formulation capecitabine@SNPs and gamma radiation: a novel metronomic approach for breast cancer treatment.Drug delivery and translational research · 2026Article
- The Influence of TDP1 Inhibitor Usnic Acid Derivative OL9-116 on the Effects of Topotecan in Human Cells.Current issues in molecular biology · 2026Article
- Association between healthy lifestyle score and risk of multiple myeloma: a case-control study.Scientific reports · 2026Article
- Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma.Annals of medicine and surgery (2012) · 2026Article
- Article
- Optimization of Pyrazolo[3,4‑ACS omega · 2026Article
- Fe/Pharmaceutics · 2026Article
- ATR-FTIR spectroscopy combined with chemometrics reveals molecular alterations and anticancer effects of Nigella sativa extract in human colon cancer cells.Scientific reports · 2026Article
- Atorvastatin as a pleiotropic anticancer agent: mechanisms, evidence, and therapeutic repurposing potential.Frontiers in immunology · 2026Review
- Tumor-directed evolution of VSVΔ51M produces novel viruses with enhanced antitumor efficacy.Frontiers in molecular biosciences · 2026Article
- BNIP3 is a key driver of breast cancer progression and a novel glycolysis-regulating biomarker.Scientific reports · 2025Article
229 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.